219 related articles for article (PubMed ID: 11249625)
1. Development of antisense oligodeoxynucleotides for transplantation.
Stepkowski SM
Curr Opin Mol Ther; 2000 Jun; 2(3):304-17. PubMed ID: 11249625
[TBL] [Abstract][Full Text] [Related]
2. Blocking of heart allograft rejection by intercellular adhesion molecule-1 antisense oligonucleotides alone or in combination with other immunosuppressive modalities.
Stepkowski SM; Tu Y; Condon TP; Bennett CF
J Immunol; 1994 Dec; 153(11):5336-46. PubMed ID: 7963586
[TBL] [Abstract][Full Text] [Related]
3. Methoxyethyl-modified intercellular adhesion molecule-1 antisense phosphorothiateoligonucleotides inhibit allograft rejection, ischemic-reperfusion injury, and cyclosporine-induced nephrotoxicity.
Chen W; Langer RM; Janczewska S; Furian L; Geary R; Qu X; Wang M; Verani R; Condon T; Stecker K; Bennett CF; Stepkowski SM
Transplantation; 2005 Feb; 79(4):401-8. PubMed ID: 15729165
[TBL] [Abstract][Full Text] [Related]
4. Protection against allograft rejection with intercellular adhesion molecule-1 antisense oligodeoxynucleotides.
Stepkowski SM; Wang ME; Condon TP; Cheng-Flournoy S; Stecker K; Graham M; Qu X; Tian L; Chen W; Kahan BD; Bennett CF
Transplantation; 1998 Sep; 66(6):699-707. PubMed ID: 9771832
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibition of IL-2 gene expression by IL-2 antisense oligonucleotides blocks heart allograft rejection.
Qu X; Kirken RA; Tian L; Wang M; Bennett CF; Stepkowski SM
Transplantation; 2001 Sep; 72(5):915-23. PubMed ID: 11571459
[TBL] [Abstract][Full Text] [Related]
6. Antisense oligonucleotides as therapeutic agents.
Galderisi U; Cascino A; Giordano A
J Cell Physiol; 1999 Nov; 181(2):251-7. PubMed ID: 10497304
[TBL] [Abstract][Full Text] [Related]
7. The clinical experience of antisense therapy to ICAM-1 in Crohn's disease.
Yacyshyn B; Bowen-Yacyshyn MB; Shanahan W
Curr Opin Mol Ther; 1999 Jun; 1(3):332-5. PubMed ID: 11713798
[TBL] [Abstract][Full Text] [Related]
8. Use of FTY 720 and ICAM-1 antisense oligonucleotides for attenuating chronic renal damage secondary to ischemia-reperfusion injury.
Troncoso P; Ortiz AM; DomÃnguez J; Kahan BD
Transplant Proc; 2005 Dec; 37(10):4284-8. PubMed ID: 16387098
[TBL] [Abstract][Full Text] [Related]
9. Phosphorothioate/methoxyethyl-modified ICAM-1 antisense oligonucleotides improves prevention of ischemic/reperfusion injury.
Stepkowski SM; Chen W; Bennett CF; Condon TP; Stecker K; Tian L; Kahan BD
Transplant Proc; 2001; 33(7-8):3705-6. PubMed ID: 11750578
[No Abstract] [Full Text] [Related]
10. Inhibition of C-raf expression by antisense oligonucleotides extends heart allograft survival in rats.
Stepkowski SM; Qu X; Wang ME; Tian L; Chen W; Wancewicz EV; Johnston JF; Bennett CF; Monia BP
Transplantation; 2000 Aug; 70(4):656-61. PubMed ID: 10972225
[TBL] [Abstract][Full Text] [Related]
11. Administration of dendritic cells transduced with antisense oligodeoxyribonucleotides targeting CD80 or CD86 prolongs allograft survival.
Liang X; Lu L; Chen Z; Vickers T; Zhang H; Fung JJ; Qian S
Transplantation; 2003 Aug; 76(4):721-9. PubMed ID: 12973117
[TBL] [Abstract][Full Text] [Related]
12. Administration of antisense oligodeoxyribonucleotides targeting NF-kappaB prolongs allograft survival via suppression of cytotoxicity.
Chen Z; Lu L; Zhang H; Dean NM; Fung JJ; Qian S
Microsurgery; 2003; 23(5):494-7. PubMed ID: 14558009
[TBL] [Abstract][Full Text] [Related]
13. Perfusion of kidneys with unformulated "naked" intercellular adhesion molecule-1 antisense oligodeoxynucleotides prevents ischemic/reperfusion injury.
Chen W; Bennett CF; Wang ME; Dragun D; Tian L; Stecker K; Clark JH; Kahan BD; Stepkowski SM
Transplantation; 1999 Sep; 68(6):880-7. PubMed ID: 10515390
[TBL] [Abstract][Full Text] [Related]
14. [Antisense oligonucleotide attenuates renal tubulointerstitial injury in mice with unilateral ureteral obstruction].
Cheng Q; Chen X; Ye Y
Zhonghua Yi Xue Za Zhi; 1999 Jul; 79(7):533-7. PubMed ID: 11715426
[TBL] [Abstract][Full Text] [Related]
15. Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
Rudin CM; Holmlund J; Fleming GF; Mani S; Stadler WM; Schumm P; Monia BP; Johnston JF; Geary R; Yu RZ; Kwoh TJ; Dorr FA; Ratain MJ
Clin Cancer Res; 2001 May; 7(5):1214-20. PubMed ID: 11350886
[TBL] [Abstract][Full Text] [Related]
16. Effects of human and murine antisense oligonucleotide inhibitors of ICAM-1 on reproductive performance, fetal development, and post-natal development in mice.
Henry SP; Denny KH; Templin MV; Yu RZ; Levin AA
Birth Defects Res B Dev Reprod Toxicol; 2004 Dec; 71(6):359-67. PubMed ID: 15617021
[TBL] [Abstract][Full Text] [Related]
17. Role of ICAM-1 in chronic hepatic allograft rejection in the rat.
Wong J; Kubes P; Zhang Y; Li Y; Urbanski SJ; Bennett CF; Lee SS
Am J Physiol Gastrointest Liver Physiol; 2002 Jul; 283(1):G196-203. PubMed ID: 12065307
[TBL] [Abstract][Full Text] [Related]
18. Prediction of antisense oligonucleotide binding affinity to a structured RNA target.
Walton SP; Stephanopoulos GN; Yarmush ML; Roth CM
Biotechnol Bioeng; 1999 Oct; 65(1):1-9. PubMed ID: 10440665
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of MD-1 expression by immunosuppressants or antisense oligodeoxynucleotides on skin allograft survival in mice.
Zhang X; Chen BC; Xiang FL; Chang S; Zhou HM; Du DF; Yuan J; Chen ZK
Transplant Proc; 2005 May; 37(4):1965-7. PubMed ID: 15919519
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, tissue distribution, and stability of antisense oligodeoxynucleotide phosphorothioate ISIS 3466 in mice.
Saijo Y; Perlaky L; Wang H; Busch H
Oncol Res; 1994; 6(6):243-9. PubMed ID: 7865900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
